Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Equity Average (2022 - 2025)

Historic Equity Average for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $73.4 million.

  • Axsome Therapeutics' Equity Average fell 2500.54% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year decrease of 2500.54%. This contributed to the annual value of $124.0 million for FY2024, which is 1748.26% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Equity Average is $73.4 million, which was down 2500.54% from $63.1 million recorded in Q2 2025.
  • Axsome Therapeutics' Equity Average's 5-year high stood at $274.2 million during Q3 2023, with a 5-year trough of $14.9 million in Q2 2022.
  • Over the past 4 years, Axsome Therapeutics' median Equity Average value was $104.3 million (recorded in 2023), while the average stood at $121.5 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Equity Average soared by 120651.83% in 2023, and later crashed by 6744.45% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Equity Average (Quarter) stood at $133.5 million in 2022, then soared by 72.52% to $230.2 million in 2023, then tumbled by 67.44% to $75.0 million in 2024, then decreased by 2.08% to $73.4 million in 2025.
  • Its last three reported values are $73.4 million in Q3 2025, $63.1 million for Q2 2025, and $55.1 million during Q1 2025.